BioNTech SE (XBUL:22UA)
лв 110 0 (0%) Market Cap: 26.37 Bil Enterprise Value: -6.97 Bil PE Ratio: 0 PB Ratio: 1.25 GF Score: 50/100

BioNTech SE at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 03:30PM GMT
Matthew Thomas Holt
JP Morgan Chase & Co, Research Division - Analyst

Good morning, everyone, and welcome to the third day of the JPMorgan Healthcare Conference. My name is Matthew Holt, and I'm a member on the biotech equity research team here at JPMorgan. It's my pleasure to introduce our next presenting company, BioNTech. And presenting today for BioNTech will be CEO and Co-Founder, Ugur Sahin. And please note that following Ugur's presentation, there's a breakout room in the Yorkshire room across the hall. So with that, I'll hand it over to Ugur.

Ugur Sahin
BioNTech SE - Co-Founder, CEO & Member of Management Board

Yes. Good morning. It's a pleasure to have the opportunity to present here. I'm Ugur Sahin. I'm Co-Founder and CEO of BioNTech, and I would like to directly start with our goals. We have -- our goal is to build a 21st Century individualized cancer immunotherapy company. And to this end, we are developing next-generation immunotherapies for cancer and other diseases. So our approach is technology agnostic. We are exploiting novel-targets

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot